These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 26088109)

  • 1. Is There a Place for Off-Label Pharmacotherapy in Cannabis Use Disorder? A Review on Efficacy and Safety.
    Laprevote V; Schwan R; Schwitzer T; Rolland B; Thome J
    Curr Pharm Des; 2015; 21(23):3298-305. PubMed ID: 26088109
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacological Treatment of Cannabis-Related Disorders: A Narrative Review.
    Gorelick DA
    Curr Pharm Des; 2016; 22(42):6409-6419. PubMed ID: 27549375
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of Cannabis Use Disorder: Current Science and Future Outlook.
    Sherman BJ; McRae-Clark AL
    Pharmacotherapy; 2016 May; 36(5):511-35. PubMed ID: 27027272
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dronabinol for the treatment of cannabis dependence: a randomized, double-blind, placebo-controlled trial.
    Levin FR; Mariani JJ; Brooks DJ; Pavlicova M; Cheng W; Nunes EV
    Drug Alcohol Depend; 2011 Jul; 116(1-3):142-50. PubMed ID: 21310551
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Depressive symptoms and cannabis use in a placebo-controlled trial of N-Acetylcysteine for adult cannabis use disorder.
    Tomko RL; Baker NL; Hood CO; Gilmore AK; McClure EA; Squeglia LM; McRae-Clark AL; Sonne SC; Gray KM
    Psychopharmacology (Berl); 2020 Feb; 237(2):479-490. PubMed ID: 31712969
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A randomized placebo-controlled trial of N-acetylcysteine for cannabis use disorder in adults.
    Gray KM; Sonne SC; McClure EA; Ghitza UE; Matthews AG; McRae-Clark AL; Carroll KM; Potter JS; Wiest K; Mooney LJ; Hasson A; Walsh SL; Lofwall MR; Babalonis S; Lindblad RW; Sparenborg S; Wahle A; King JS; Baker NL; Tomko RL; Haynes LF; Vandrey RG; Levin FR
    Drug Alcohol Depend; 2017 Aug; 177():249-257. PubMed ID: 28623823
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A proof-of-concept randomized controlled study of gabapentin: effects on cannabis use, withdrawal and executive function deficits in cannabis-dependent adults.
    Mason BJ; Crean R; Goodell V; Light JM; Quello S; Shadan F; Buffkins K; Kyle M; Adusumalli M; Begovic A; Rao S
    Neuropsychopharmacology; 2012 Jun; 37(7):1689-98. PubMed ID: 22373942
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Separate and combined effects of gabapentin and [INCREMENT]9-tetrahydrocannabinol in humans discriminating [INCREMENT]9-tetrahydrocannabinol.
    Lile JA; Wesley MJ; Kelly TH; Hays LR
    Behav Pharmacol; 2016 Apr; 27(2-3 Spec Issue):215-24. PubMed ID: 26313650
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nabiximols combined with motivational enhancement/cognitive behavioral therapy for the treatment of cannabis dependence: A pilot randomized clinical trial.
    Trigo JM; Soliman A; Quilty LC; Fischer B; Rehm J; Selby P; Barnes AJ; Huestis MA; George TP; Streiner DL; Staios G; Le Foll B
    PLoS One; 2018; 13(1):e0190768. PubMed ID: 29385147
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cannabinoid replacement therapy (CRT): Nabiximols (Sativex) as a novel treatment for cannabis withdrawal.
    Allsop DJ; Lintzeris N; Copeland J; Dunlop A; McGregor IS
    Clin Pharmacol Ther; 2015 Jun; 97(6):571-4. PubMed ID: 25777582
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nabiximols as an agonist replacement therapy during cannabis withdrawal: a randomized clinical trial.
    Allsop DJ; Copeland J; Lintzeris N; Dunlop AJ; Montebello M; Sadler C; Rivas GR; Holland RM; Muhleisen P; Norberg MM; Booth J; McGregor IS
    JAMA Psychiatry; 2014 Mar; 71(3):281-91. PubMed ID: 24430917
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Editorial: Off-label Treatments for Mental Health: Inappropriate or Unavoidable? A Special Issue to Help Get Through the Maze.
    Rolland B; Amad A
    Curr Pharm Des; 2015; 21(23):3274-5. PubMed ID: 26238988
    [No Abstract]   [Full Text] [Related]  

  • 13. Evidence, regulation and 'rational' prescribing: the case of gabapentin for neuropathic pain.
    Ghinea N; Lipworth W; Kerridge I
    J Eval Clin Pract; 2015 Feb; 21(1):28-33. PubMed ID: 24986307
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Influence of tiagabine maintenance on cannabis effects and related behaviors in daily cannabis users.
    Wesley MJ; Westgate PM; Stoops WW; Kelly TH; Hays LR; Lile JA
    Exp Clin Psychopharmacol; 2018 Jun; 26(3):310-319. PubMed ID: 29863387
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Abstinence and reduced frequency of use are associated with improvements in quality of life among treatment-seekers with cannabis use disorder.
    Brezing CA; Choi CJ; Pavlicova M; Brooks D; Mahony AL; Mariani JJ; Levin FR
    Am J Addict; 2018 Mar; 27(2):101-107. PubMed ID: 29457671
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biological rationale and potential clinical use of gabapentin and pregabalin in bipolar disorder, insomnia and anxiety: protocol for a systematic review and meta-analysis.
    Houghton KT; Forrest A; Awad A; Atkinson LZ; Stockton S; Harrison PJ; Geddes JR; Cipriani A
    BMJ Open; 2017 Mar; 7(3):e013433. PubMed ID: 28348186
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Off-Label Use of Medications for Treatment of Benzodiazepine Use Disorder.
    Sabioni P; Bertram J; Le Foll B
    Curr Pharm Des; 2015; 21(23):3306-10. PubMed ID: 26088120
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intended and unintended consequences of the gabapentin off-label marketing lawsuit among patients with bipolar disorder.
    Chace MJ; Zhang F; Fullerton CA; Huskamp HA; Gilden D; Soumerai SB
    J Clin Psychiatry; 2012 Nov; 73(11):1388-94. PubMed ID: 23146199
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Correlates of treatment engagement and client outcomes: results of a randomised controlled trial of nabiximols for the treatment of cannabis use disorder.
    Mills L; Dunlop A; Montebello M; Copeland J; Bruno R; Jefferies M; Mcgregor I; Lintzeris N
    Subst Abuse Treat Prev Policy; 2022 Oct; 17(1):67. PubMed ID: 36209081
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Results from a randomized, double-blind, placebo-controlled, crossover, multimodal-MRI pilot study of gabapentin for co-occurring bipolar and cannabis use disorders.
    Prisciandaro JJ; Mellick W; Squeglia LM; Hix S; Arnold L; Tolliver BK
    Addict Biol; 2022 Jan; 27(1):e13085. PubMed ID: 34390300
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.